NCT02510248 - First in Human Study of AL-704; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

November 24, 2015

Study Completion Date

November 24, 2015

Conditions

Chronic Hepatitits C

Interventions

DRUG

AL-704

JNJ-54257099 (also known as ALS-022704 or AL-704) is a hepatitis C virus (HCV) nonstructural (NS)5B inhibitor, belonging to the nucleoside / nucleotide inhibitor class, and is being developed as an orally administered anti-HCV therapeutic.

DRUG

Placebo

Placebo to match AL-704

Trial Locations (3)

355042

Biotrial, Rennes

Unknown

Arensia, Tbilisi

Arensia, Chisinau